ISBN: 978-1-4731-3093-7 Study Intervention and comparison (in HF clinic unless stated otherwise) Population Primary studies included Range of intervention times: 3- available As aggregate data: BATTLESCARRED, Berger 2010, Christchurch pilot, PRIMA, PROTECT, Shochat 2012, SIGNAL- HF, STARS-BNP, TIME-CHF Troughton (Brunner-la ) Troughton review NP-guided therapy versus Usual care (review refers to as Clinically-guided therapy ) Range of intervention times: 3- Subgroups for age, and others including CKD As IPD: BATTLESCARRED, Berger 2010 (labelled Vienna ), Christchurch pilot, PRIMA, PROTECT, SIGNAL-HF, TIME-CHF, UPSTEP NP: natriuretic peptides including BNP and NT-proBNP Table 80: Summary of primary studies included in the review Study Intervention and comparison (in HF clinic unless stated otherwise) Population Outcomes Comments NP monitoring: Therapy increased to target (BNP level < Clinical monitoring: Therapy intensified to reach target (congestion score and months Age mean: 69(10) Recently hospitalised and NYHA II/III HTA IPD: Mortality by age All-cause admission by age Recruited on discharge BATTLESCARRE D trial: Lainchbury (Lainchbury ) NP monitoring: Therapy increased to achieve clinical and NP target (congestion score<2 Clinical monitoring: Therapy increased to meet target months No protocol: Discharged to primary care Age > 18 mean: Recently hospitalised HF- admission Elevated NP (NT- proBNP > 50 pmol/L) HTA aggregate: Mortality by age Troughton IPD: HF admission Study papers: Quality of life renal function, no monitoring arm Recruited from hospital Chronic Heart Failure Monitoring NICE 2018. All rights reserved. Subject to Notice of rights. 